Laekna Announces Clinical Collaboration With Lilly
Shanghai – November 20, 2024 – Cooley advised Laekna (HKSE: 2105.HK), a global biotech company focused on novel drug development for metabolic and cancer diseases, on its clinical collaboration with Eli Lilly and Company to accelerate the development of LAE102, a novel ActRIIA mAb as a treatment for obesity. The collaboration includes clinical development of LAE102 through a phase 1 study, including obese patients, with Lilly providing funding, resources and expertise to accelerate research and development timelines. Laekna, which focuses on novel therapies for cancer, metabolic diseases and liver fibrosis, will retain global rights to LAE102.
Lawyers Yiming Liu, Bin Wang and Zack Gong led the Cooley team advising Laekna.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.